A2A Pharmaceuticals Inc.
1 clinical trials · Sponsor
◉ Watch A2A Pharmaceuticals Inc.
| Record | Firm | Date |
|---|---|---|
| A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases (NCT06136884) | A2A Pharmaceuticals Inc. | 2023-11-02 |
Track A2A Pharmaceuticals Inc. automatically
Every clearance here is in the API, with alerts when new ones post.